Edition:
United States

Trinity Biotech PLC (TRIB.OQ)

TRIB.OQ on NASDAQ Stock Exchange Global Select Market

5.60USD
28 Mar 2017
Change (% chg)

$0.07 (+1.27%)
Prev Close
$5.53
Open
$5.53
Day's High
$5.67
Day's Low
$5.53
Volume
5,612
Avg. Vol
28,054
52-wk High
$13.65
52-wk Low
$5.29

Latest Key Developments (Source: Significant Developments)

Lapides Asset Management LLC reports 5.1 pct passive stake in Trinity Biotech
Wednesday, 15 Mar 2017 11:13am EDT 

Trinity Biotech Plc :Lapides Asset Management LLC reports 5.1 percent passive stake in trinity Biotech Plc as of March 6 - sec filing.  Full Article

Trinity Biotech quarterly EPS $0.043
Tuesday, 14 Mar 2017 09:13am EDT 

Trinity Biotech Plc : Trinity biotech announces quarter 4 and fiscal year 2016 financial results . Quarterly earnings per share $0.043 . Q4 revenue $23.7 million versus i/b/e/s view $25.8 million . Trinity biotech plc - during quarter company recognised once-off charges amounting to $105.8 million net of tax .Trinity biotech plc - with closure of our swedish facility, going forward we will operate at close to a free cash flow break even position.  Full Article

Trinity Biotech announces withdrawal of Troponin FDA 510(k) submission
Tuesday, 4 Oct 2016 08:30am EDT 

Trinity Biotech Plc : Trinity biotech announces withdrawal of Troponin FDA 510(k) submission . FDA asked trinity to consider withdrawing their submission, due to some concerns they have about submission . To move technology from swedish facility to facility in ireland where it will be incorporated into research and development,manufacturing infrastructure . Moving of technology will result in closure of uppsala facility in sweden, which will result in approximately 40 redundancies . Trinity biotech announces withdrawal of troponin fda 510(k) submission . Held a meeting with fda on thursday 29 september, in order to obtain an update on company's meritas troponin submission . Fda asked trinity to consider withdrawing their submission, due to some concerns they have about submission . Fda's primary concerns relate to device's operating temperature range . "over coming weeks we will engage with fda to gain a better understanding of nature of their concerns" . Fda concerns also relate to troponin-i clinical performance not being consistent with clinical performance data .Will also recognise a non-cash write-off in excess of $50m, representing costs incurred on project, which will be recognised in q4.  Full Article

Trinity Biotech plc announces dividend
Thursday, 30 Apr 2015 08:23am EDT 

Trinity Biotech plc:Proposing dividend of 22 cents per ADR (5.5 cents per 'A' ordinary share), which is consistent with dividend paid in 2014.Says payment of this dividend is subject to shareholder approval, which will be sought at company's forthcoming AGM to be held on June 5.Subject to this approval being granted, record date will be June 9, 2015 and payment will follow about 3 weeks later.  Full Article

Trinity Biotech plc closes offering of $115 million of 4.00 pct. exchangeable senior notes due 2045
Thursday, 9 Apr 2015 01:11pm EDT 

Trinity Biotech plc:Says that Trinity Biotech Investment Limited, its wholly-owned subsidiary, closed its offering of $115 million aggregate principal amount of Exchangeable Senior Notes due 2045 in a private offering to qualified institutional buyers.The closing included the exercise in full of the initial purchasers' option to purchase up to an additional $15 million aggregate principal amount of the notes.The notes will mature on April 1, 2045, unless earlier purchased, redeemed or exchanged.The Issuer expects that the net proceeds from the offering will be about $110.9 million, after deducting underwriting discounts and estimated expenses of the offering.Trinity Biotech plc currently expects to use the net proceeds from the offering for potential future acquisitions and for general corporate purposes, which may include continued product development and commercialization.The notes are senior unsecured obligations of the Issuer and accrue interest at an annual rate of 4.00 pct. from the date on which the notes are originally issued, payable semi-annually in arrears on April 1 and Oct. 1 of each year, beginning on Oct. 1, 2015.  Full Article

More From Around the Web

BRIEF-Lapides Asset Management LLC reports 5.1 pct passive stake in Trinity Biotech

* Lapides Asset Management LLC reports 5.1 percent passive stake in trinity Biotech Plc as of March 6 - sec filing Source text : http://bit.ly/2msqjyg Further company coverage: